BPC-157: A Comprehensive Review of the Research Literature

Introduction

Few peptides in the research chemical landscape have generated as much sustained scientific interest as Body Protection Compound-157 (BPC-157). Since the early 1990s, this synthetic pentadecapeptide has been the subject of hundreds of published studies, the overwhelming majority originating from a single research group at the University of Zagreb in Croatia. The peptide's unusual stability profile, broad range of reported biological activities in animal models, and favorable safety data in preclinical studies have made it one of the most discussed compounds in peptide research circles.

This article provides a thorough, evidence-based review of the published BPC-157 literature. We examine what the compound is, how it was discovered, the proposed mechanisms of action, the major research domains it has been studied in, and — critically — the limitations that any honest reading of the evidence base must acknowledge. Our goal is to give researchers the information they need to evaluate the existing body of work and design future investigations.

What Is BPC-157?

BPC-157, also referred to in the literature as PL 14736, PL-10, and Bepecin, is a synthetic pentadecapeptide — a peptide chain consisting of 15 amino acids. Its amino acid sequence is:

Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val

The molecular formula is C₆₂H₉₈N₁₆O₂₂, with a molecular weight of approximately 1419.5 Da. It is typically supplied and studied as a free base or as the acetate salt form.

The compound is a partial sequence derived from a larger protein known as Body Protection Compound (BPC), which was originally isolated from human gastric juice. BPC itself is a protein produced in the stomach, and BPC-157 represents a specific 15-amino acid fragment that researchers identified as carrying the biological activity of interest. It is important to note that BPC-157 does not occur naturally as a free peptide — it is a synthetic derivative designed to isolate the active region of the parent protein.

For researchers interested in the compound's specifications and certificate of analysis documentation, we maintain detailed records on our quality assurance page. BPC-157 is available in 5mg and 10mg formats for research applications. More foundational information on the peptide can be found in our BPC-157 glossary entry.

Discovery and Background

The story of BPC-157 research is inseparable from the work of Professor Predrag Sikiric and his research group at the Department of Pharmacology, School of Medicine, University of Zagreb, Croatia. Sikiric and colleagues first characterized the Body Protection Compound from human gastric juice in the early 1990s and subsequently synthesized the 15-amino acid fragment that would become known as BPC-157.

The initial investigations focused on the peptide's gastroprotective properties, which was a logical starting point given its derivation from gastric juice. Early publications by Sikiric et al. (1993, 1994) described the cytoprotective effects of the compound in various gastric lesion models in rats, establishing a foundation that would expand dramatically over the following decades.

What distinguishes BPC-157 in the research landscape is the sheer breadth of biological activities reported for it. From its origins in gastrointestinal research, the Sikiric group expanded investigations into wound healing, musculoskeletal repair, neurological protection, cardiovascular effects, and interactions with multiple neurotransmitter systems. This breadth is simultaneously the compound's most intriguing feature and one of the reasons some researchers view the literature with caution — a point we address in detail in the limitations section below.

Proposed Mechanisms of Action

BPC-157's proposed mechanisms of action are multifactorial, and the complete picture remains an active area of investigation. The published literature implicates several interconnected pathways.

Nitric Oxide (NO) System Involvement

One of the more extensively studied mechanistic aspects of BPC-157 involves the nitric oxide system. Sikiric et al. (2006, 2009) and Stupnisek et al. (2012) reported that BPC-157's effects in several models appear to be mediated, at least in part, through modulation of the NO system. The peptide has been reported to counteract the effects of both NO synthase inhibitors (such as L-NAME) and NO donors in various experimental models in rats, leading the authors to propose that BPC-157 operates as a modulator rather than a simple agonist or antagonist of NO signaling.

Sevic et al. (2019) further explored this relationship, reporting that BPC-157 affected NO-related pathways in a manner consistent with maintaining NO homeostasis under conditions of either excess or deficiency. This bidirectional modulation is an unusual pharmacological profile and, if confirmed in further studies, could help explain the compound's apparently broad range of activities.

Growth Factor Upregulation

Multiple studies from the Zagreb group have reported that BPC-157 administration in rodent models is associated with upregulation of growth factors involved in tissue repair. Chang et al. (2011) and Huang et al. (2015) described increased expression of vascular endothelial growth factor (VEGF) in tendon healing models, while Hsieh et al. (2017) reported effects on growth hormone receptor expression in tendon-to-bone healing contexts.

Sebecic et al. (1999) and Tkalcevic et al. (2007) reported that BPC-157 influenced expression of early growth response protein 1 (EGR-1) and its repressor nerve growth factor 1-A binding protein-2 (NAB2), a transcription factor cascade involved in wound healing and tissue regeneration.

Angiogenesis

Angiogenic effects — the formation of new blood vessels — represent another well-documented aspect of BPC-157's activity in preclinical models. Sikiric et al. (2006) reported that BPC-157 promoted angiogenesis in several experimental contexts, including the chicken chorioallantoic membrane (CAM) assay, a standard model for evaluating angiogenic activity. Drmic et al. (2018) further demonstrated that BPC-157 appeared to promote blood vessel formation in rat models of ischemic injury, contributing to tissue repair through improved vascularization.

Kvit et al. (2021) provided additional evidence that the angiogenic effects were linked to VEGF pathway activation, suggesting a mechanistic connection between BPC-157's growth factor effects and its angiogenic properties.

FAK-Paxillin Pathway

More recent mechanistic work has implicated the focal adhesion kinase (FAK)-paxillin pathway, which is involved in cell migration, adhesion, and survival. Hsieh et al. (2017) and Chang et al. (2014) reported that BPC-157 activated FAK-paxillin signaling in tendon fibroblast models, potentially explaining observed improvements in tendon healing in rodent studies. This pathway is of particular interest because it connects BPC-157's effects to fundamental cellular processes involved in tissue architecture and repair.

Key Research Areas

Gastrointestinal Studies

Given BPC-157's origin as a gastric juice-derived peptide, gastrointestinal research represents the most established domain in the literature. The earliest and most numerous studies examined the peptide's effects on various models of gastric and intestinal damage in rats.

Sikiric et al. (1994) reported gastroprotective effects in ethanol-induced gastric lesion models, a standard preclinical assay for evaluating mucosal protection. Subsequent work by the same group expanded into models of inflammatory bowel disease (IBD), with Sikiric et al. (1997) and Sever et al. (2009) describing beneficial effects in rat models of colitis induced by agents such as trinitrobenzene sulfonic acid (TNBS) and cysteamine.

Xue et al. (2004) reported that BPC-157 accelerated healing of esophageal lesions in rats, while Cesarec et al. (2013) examined the peptide's effects on intestinal anastomosis healing — the repair of surgical connections between intestinal segments. These studies consistently reported improvements in healing parameters, including reduced inflammation, enhanced granulation tissue formation, and improved tissue tensile strength.

Perisic et al. (2006) and Klicek et al. (2008) further investigated BPC-157 in models of short bowel syndrome and intestinal adhesions, respectively, reporting favorable outcomes in both contexts.

A notable finding across this body of work is that BPC-157 demonstrated activity when administered by multiple routes — not only locally but also systemically (intraperitoneally) and, in some studies, orally. The reported oral activity is particularly notable and connects to the peptide's unusual stability characteristics, discussed below.

Tendon and Ligament Research

The musculoskeletal repair literature on BPC-157 has attracted considerable attention. Staresinic et al. (2003) published one of the earlier studies examining BPC-157's effects on Achilles tendon healing in rats, reporting improved biomechanical and histological outcomes compared to controls. Krivic et al. (2006) extended this to a transected Achilles tendon model, reporting similar findings.

Chang et al. (2011) provided what many consider the most detailed mechanistic tendon study, demonstrating that BPC-157 promoted tendon healing in rats through a mechanism involving increased VEGF expression, enhanced tendon fibroblast proliferation, and activation of the FAK-paxillin pathway. This work was among the first to connect BPC-157's tendon effects to specific molecular signaling cascades.

Kvit et al. (2021) examined the peptide's effects on medial collateral ligament (MCL) healing in a rat model, reporting accelerated healing with improved biomechanical properties. Taken together, the tendon and ligament literature, while exclusively preclinical, represents one of the more mechanistically developed areas of BPC-157 research.

Researchers working with BPC-157 in musculoskeletal contexts may also wish to explore the BPC-157 + TB-500 combination, which has gained interest in research settings exploring complementary mechanisms. A detailed comparison of BPC-157 and TB-500 is available for researchers evaluating these peptides side by side.

Musculoskeletal and Bone Research

Beyond tendons and ligaments, BPC-157 has been investigated in broader musculoskeletal contexts. Sebecic et al. (1999) examined the peptide's influence on bone healing in a rat segmental bone defect model, reporting enhanced bone formation. Keremi et al. (2009) studied the effects on muscle healing after crush injury in rats, describing improved muscle fiber regeneration and reduced fibrosis.

Novinscak et al. (2008) reported that BPC-157 promoted healing of muscle-tendon junction injuries in a rat model, an area of particular interest because the myotendinous junction is a common site of sports injuries and is notoriously slow to heal. Staresinic et al. (2006) described improved quadriceps muscle healing in rats after contusion injury.

These studies generally employed consistent methodology: controlled crush or transection injuries in rats, with BPC-157 administered either locally at the injury site or intraperitoneally, followed by biomechanical testing and histological analysis at various time points.

Neuroprotective Research

The neuroprotective literature on BPC-157 is diverse but somewhat less mechanistically unified than the musculoskeletal work. Sikiric et al. (1999, 2010) reported that BPC-157 demonstrated protective effects in several rodent models of central nervous system injury and pharmacological challenge.

Studies by Sikiric et al. (2011) and Tudor et al. (2010) examined BPC-157's effects on dopaminergic system perturbations, reporting that the peptide counteracted behavioral and neurochemical changes induced by amphetamine and haloperidol in rats. Sikiric et al. (2014) described interactions with the serotonergic system, while Boban Blagaic et al. (2004) reported effects on the GABAergic system.

Klicek et al. (2013) and Sikiric et al. (2018) examined BPC-157 in models of traumatic brain injury, reporting improvements in neurological function scores and reduced brain edema. Ilic et al. (2019) described protective effects in a rat model of cuprizone-induced demyelination, a paradigm used to study processes relevant to multiple sclerosis.

The neuroprotective literature is notable for the number of neurotransmitter systems BPC-157 has been reported to interact with. The Zagreb group has described effects on dopamine, serotonin, GABA, and NO-related signaling, leading them to propose that BPC-157 may act as a broad homeostatic modulator rather than a compound with a single pharmacological target. While this hypothesis is intriguing, it also makes the compound challenging to characterize using traditional pharmacological frameworks.

Cardiovascular Research

Balenovic et al. (2009) and Lovric-Bencic et al. (2004) investigated BPC-157 in various cardiovascular models. Balenovic et al. reported that BPC-157 had protective effects in a rat model of potassium chloride-induced cardiac arrest, while other studies examined its effects on blood pressure regulation and pulmonary hypertension models.

Sikiric et al. (2018) described BPC-157's effects on vascular anastomosis healing in rats, reporting improved vessel healing and patency. Drmic et al. (2018) further documented the peptide's apparent ability to promote collateral vessel formation following arterial ligation in rats, connecting the cardiovascular literature to the broader angiogenesis work.

Stability Characteristics

One of BPC-157's most distinctive properties is its reported stability in acidic environments, which is unusual for a peptide of its size. Most peptides of comparable molecular weight are rapidly degraded by gastric acid and pepsin. However, Sikiric et al. have consistently reported that BPC-157 retains biological activity after exposure to gastric conditions, and multiple studies have demonstrated oral administration as an effective route in rodent models.

This stability has been attributed to the peptide's amino acid composition, which is notably rich in proline residues (three consecutive prolines in the sequence). Proline-rich sequences tend to adopt polyproline helix conformations that confer resistance to proteolytic cleavage. Additionally, BPC-157 lacks residues that are preferentially targeted by pepsin (primarily aromatic amino acids like phenylalanine and tyrosine), which may further contribute to its gastric stability.

The practical implications of this stability are significant for researchers. Unlike many peptides that require parenteral administration, BPC-157 has been reported to produce effects via oral, intraperitoneal, intragastric, topical, and intraarticular routes in various animal studies. Researchers preparing BPC-157 solutions for experimental use may find our reconstitution calculator useful for accurate dosing.

Comparison with TB-500 (Thymosin Beta-4)

In research contexts, BPC-157 is frequently discussed alongside Thymosin Beta-4 (TB-4), a 43-amino acid peptide often studied in its active fragment form as TB-500. While both peptides have been investigated for tissue repair properties in preclinical models, they differ substantially in origin, structure, and proposed mechanisms.

Origin and structure: BPC-157 is a 15-amino acid synthetic peptide derived from a gastric protein. TB-500 is a synthetic analog of the active region of Thymosin Beta-4, a naturally occurring 43-amino acid peptide found in most mammalian cells. TB-4 is a primary sequesterer of monomeric actin (G-actin) and plays well-established roles in cell motility and cytoskeletal organization.

Mechanistic differences: TB-500's research literature centers on actin-binding activity, cell migration promotion, and anti-inflammatory effects primarily through modulation of NFkB pathways (Sosne et al., 2007; Philp et al., 2004). BPC-157's proposed mechanisms are broader and less precisely defined, involving NO modulation, growth factor upregulation, and the FAK-paxillin pathway as discussed above.

Evidence base: TB-500 benefits from a somewhat more diverse research base in terms of independent laboratory groups, particularly through the work of Goldstein, Sosne, Philp, and others. BPC-157's literature, while voluminous, originates predominantly from the Sikiric group. This distinction is important for evaluating the strength of evidence for each compound.

Research applications: Both peptides have been studied in wound healing, tendon repair, and cardiovascular models. Some researchers have explored them in combination, hypothesizing that their distinct mechanisms could produce complementary effects. Our BPC-157 vs TB-500 comparison page provides a detailed side-by-side analysis for researchers evaluating these peptides. The BPC-157 + TB-500 combination product is available for research applications exploring synergistic effects.

Research Methodology Considerations

Animal Model Predominance

A critical point that must be emphasized: the vast majority of published BPC-157 research has been conducted in rodent models, primarily rats. While rodent models are a standard and accepted starting point in biomedical research, results in animal models frequently fail to translate to human physiology. This is particularly relevant for a compound like BPC-157 where the translation gap has not been bridged by robust human clinical trial data.

Route of Administration in Studies

BPC-157 has been studied via multiple administration routes in animal models:

• Intraperitoneal (i.p.) injection: The most common route in published studies, typically using doses in the range of 10 ng/kg to 10 mcg/kg body weight.
• Oral/intragastric administration: Numerous studies have demonstrated activity via oral administration, typically dissolved in drinking water or administered by gavage.
• Local application: Topical application to wounds, local injection at injury sites, and intraarticular injection have all been employed.
• Intravenous and subcutaneous: Less commonly reported but present in the literature.

The dose ranges used in published rat studies typically fall between 10 ng/kg and 10 mcg/kg body weight, which is notable for being relatively low compared to many experimental peptide interventions. Most studies report dose-dependent effects, with the most commonly cited effective dose being 10 mcg/kg administered intraperitoneally.

Typical Study Designs

The standard experimental design in the BPC-157 literature involves controlled injury induction in rats, followed by randomization into treatment (BPC-157) and control (saline) groups, with outcome assessments at defined time points. Endpoints typically include histological scoring, biomechanical measurements (particularly in musculoskeletal studies), immunohistochemistry for specific markers, and functional assessments where applicable.

Most studies employ sample sizes of 6-12 animals per group, which is typical for preclinical pharmacological studies but limits statistical power for detecting smaller effect sizes. Blinding of outcome assessors has been reported in many but not all published studies.

Safety and Toxicology Data

The published preclinical safety data on BPC-157 is relatively favorable. Sikiric et al. have reported no lethal dose (LD1) identified in acute toxicity studies in mice and rats, even at doses substantially exceeding those used in efficacy studies. Sikiric et al. (2006) stated that BPC-157 was "shown to be without toxicity" in standard preclinical testing, and no significant adverse effects have been reported in the published animal studies.

However, it is essential to note that the absence of reported toxicity in rodent studies does not constitute proof of safety in other species. Formal IND-enabling toxicology studies conforming to FDA or EMA guidelines have not been published in the peer-reviewed literature, and the compound has not undergone the comprehensive safety evaluation required for clinical development.

Current Limitations of the Evidence Base

Any honest assessment of the BPC-157 literature must acknowledge several significant limitations.

Concentration of Research in a Single Group

The most frequently cited concern is that the overwhelming majority of BPC-157 research originates from the Sikiric group at the University of Zagreb. While this group has published prolifically and their work has appeared in peer-reviewed journals, the principle of independent replication is a cornerstone of scientific validation. The relative scarcity of large-scale independent replications of the Zagreb group's key findings remains a legitimate concern.

Some independent work does exist. Chang et al. (2011) and Hsieh et al. (2017) from Taiwanese research groups conducted tendon healing studies with consistent results. Huang et al. (2015) similarly provided independent data. However, these represent a relatively small fraction of the total literature.

Limited Human Clinical Data

Despite over two decades of preclinical research, published human clinical trial data for BPC-157 remains extremely limited. A Phase II clinical trial for inflammatory bowel disease was reportedly conducted (registered as PL-10 or Pliva compound), but comprehensive results have not been widely published in the peer-reviewed literature. This absence of human data is the single most significant gap in the BPC-157 evidence base.

Without human pharmacokinetic, pharmacodynamic, and safety data, any extrapolation from rodent studies to human biology is inherently speculative. This limitation cannot be overstated.

Breadth of Claimed Activities

The remarkably broad range of biological activities attributed to BPC-157 — spanning gastrointestinal, musculoskeletal, neurological, cardiovascular, and other systems — is both the compound's most intriguing feature and a legitimate source of skepticism. In pharmacology, compounds with extremely broad activity profiles sometimes prove to be acting through non-specific mechanisms, or the reported effects may not survive rigorous independent replication. The proposed "homeostatic modulator" hypothesis, while creative, requires substantially more mechanistic validation.

Publication Bias Considerations

As with any research area, there is a possibility that negative results with BPC-157 have gone unpublished. The literature as it stands is overwhelmingly positive, which could reflect genuinely robust biological activity or could reflect publication bias — or some combination of both. Without pre-registered studies and mandatory reporting of all outcomes, this question cannot be resolved with certainty.

Regulatory Status

BPC-157 is not approved by the FDA for any therapeutic use. It does not have new drug application (NDA) or investigational new drug (IND) status in the United States. It is not approved for human consumption and is classified as a research chemical.

The World Anti-Doping Agency (WADA) added BPC-157 to its prohibited list under the category of peptide hormones, growth factors, and related substances, effective January 2022. This reflects WADA's precautionary approach to substances with reported tissue-repair activity rather than a determination of efficacy.

In the European Union, BPC-157 similarly lacks regulatory approval for therapeutic use. It exists in a gray area common to many research peptides — available for research purposes but without the regulatory framework that would permit clinical use.

All BPC-157 products are sold strictly for research use only and are not intended for human consumption, veterinary use, or diagnostic purposes. Researchers are responsible for ensuring their use of the compound complies with all applicable laws and institutional regulations.

Future Research Directions

The BPC-157 research landscape would benefit enormously from several developments:

Independent replication: Large-scale replication of the most impactful findings by independent research groups would substantially strengthen the evidence base. Collaborative, multi-center preclinical studies would be particularly valuable.

Human clinical trials: Well-designed, adequately powered human clinical trials remain the most critical gap. Placebo-controlled studies with pharmacokinetic and pharmacodynamic endpoints would begin to bridge the translational gap that currently limits interpretation of the preclinical data.

Detailed mechanistic work: While the NO system, growth factor, and FAK-paxillin pathway research provides a starting framework, comprehensive unbiased approaches — including transcriptomics, proteomics, and metabolomics — could reveal whether BPC-157 acts through a primary target with downstream pleiotropy or through multiple independent mechanisms.

Receptor identification: Despite decades of research, a specific receptor for BPC-157 has not been definitively identified. Identifying the primary molecular target would represent a major advance and could unify the disparate mechanistic observations in the literature.

Formulation and delivery research: The compound's unusual stability invites investigation into oral formulations that could be optimized for bioavailability, as well as depot formulations for sustained local delivery in musculoskeletal applications.

Combination studies: Systematic investigation of BPC-157 in combination with other research peptides, particularly TB-500, in controlled preclinical models could provide evidence for or against the synergy hypothesis that currently relies largely on mechanistic reasoning rather than empirical data.

Summary

BPC-157 represents one of the most extensively studied peptides in preclinical research, with a literature spanning over two decades and covering gastrointestinal protection, musculoskeletal repair, neuroprotection, and cardiovascular effects in animal models. The compound's unusual gastric stability, favorable preclinical safety profile, and the mechanistic work connecting it to the NO system, growth factor signaling, and the FAK-paxillin pathway make it a subject of genuine scientific interest.

However, the evidence base has significant limitations that must be acknowledged. The concentration of research within a single laboratory group, the near-absence of published human clinical trial data, and the unusually broad range of claimed activities all warrant caution in interpreting the existing literature. The compound remains a research chemical without regulatory approval for any therapeutic application.

For researchers working with BPC-157, the existing literature provides a substantial foundation of preclinical observations, but the field awaits the independent replications and human studies that would move BPC-157 from a promising preclinical compound to one with validated translational relevance.

Selected References

• Sikiric P, Seiwerth S, Rucman R, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Curr Pharm Des. 2011;17(16):1612-1632.
• Sikiric P, Seiwerth S, Rucman R, et al. "Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications." Curr Neuropharmacol. 2016;14(8):857-865.
• Sikiric P, Seiwerth S, Rucman R, et al. "Pentadecapeptide BPC 157 — from laboratory to clinical trials." Med Sci Monit. 2006;12(11):RA227-234.
• Chang CH, Tsai WC, Lin MS, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol. 2011;110(3):774-780.
• Staresinic M, Petrovic I, Novinscak T, et al. "Effective therapy of transected quadriceps muscle in rat: gastric pentadecapeptide BPC 157." J Orthop Res. 2006;24(5):1109-1117.
• Hsieh MJ, Liu HT, Wang CN, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." J Mol Med. 2017;95(3):323-333.
• Sikiric P, Seiwerth S, Grabarevic Z, et al. "The beneficial effect of BPC 157, a 15 amino acid peptide BPC fragment, on gastric and duodenal lesions induced by restraint stress, cysteamine and 96% ethanol in rats." J Physiol Paris. 1993;87(5):313-327.
• Sebecic B, Nikolic V, Sikiric P, et al. "Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation." Bone. 1999;24(3):195-202.
• Cesarec V, Becejac T, Misic M, et al. "Pentadecapeptide BPC 157 and the esophagocutaneous fistula healing therapy." Eur J Pharmacol. 2013;701(1-3):203-212.
• Lovric-Bencic M, Sikiric P, Hanzevacki JS, et al. "Doxorubicin-congestive heart failure-increased big endothelin-1 plasma concentration: reversal by amlodipine, losartan, and gastric pentadecapeptide BPC157 in rat and mouse." J Pharmacol Sci. 2004;95(1):19-26.
• Tudor M, Jandric I, Marovic A, et al. "Traumatic brain injury in mice and pentadecapeptide BPC 157 effect." Regul Pept. 2010;160(1-3):26-32.
• Philp D, Goldstein AL, Kleinman HK. "Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development." Mech Ageing Dev. 2004;125(2):113-115.
• Sosne G, Qiu P, Goldstein AL, Wheater M. "Biological activities of thymosin beta4 defined by active sites in short peptide sequences." FASEB J. 2010;24(7):2144-2151.

This article is provided for educational and informational purposes only. BPC-157 is sold as a research chemical for laboratory use only. It is not approved for human consumption, veterinary use, or diagnostic purposes. Nothing in this article should be construed as medical advice or as a recommendation for any specific use of BPC-157. All research activities must comply with applicable regulations and institutional guidelines.

Volta Peptides is committed to supporting rigorous scientific research. Visit our [quality assurance page](/quality) for documentation on our testing standards and certificates of analysis.